SCHEMBL5144877

SCHEMBL5144877

CC(=O)Oc1ccc2ncnc(Nc3ccccc3)c2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.70
MAPK1 P28482 3/20 0.60
KDM4E B2RXH2 1/20 0.60
HTT P42858 1/20 0.60
MAPT P10636 1/20 0.59
GRM1 Q13255 1/20 0.59
ERBB2 P04626 3/20 0.57
BRAF P15056 3/20 0.56
USP2 O75604 2/20 0.56
LMNA P02545 2/20 0.56
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 2/20 0.56
CLK4 Q9HAZ1 2/20 0.56
FYN P06241 1/20 0.56
SRC P12931 1/20 0.56
MEN1 O00255 1/20 0.56
CYP2C9 P11712 1/20 0.56
TSHR P16473 1/20 0.56
CYP2C19 P33261 1/20 0.56
KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8364174 0.89 EGFR (0.75) EGFRERBB2CLK4
Hydrochloric Acid SCHEMBL8810261 0.88 EGFR (0.74) EGFRERBB2CLK4
SCHEMBL4740851 0.87 EGFR (0.66) EGFRMAPK1KDM4EHTTMAPT
SCHEMBL642238 0.84 EGFR (0.71) EGFRMAPTERBB2BRAFLMNA
SCHEMBL17836949 0.84 EGFR (0.70) EGFRRETKDR
SCHEMBL7766632 0.83 EGFR (0.57) EGFRMAPTGRM1ERBB2BRAF
SCHEMBL6954080 0.83 EGFR (1.00) EGFRMAPK1KDM4EHTTMAPT
Hydrochloric Acid SCHEMBL8305110 0.82 EGFR (0.51) EGFRKDM4EHTTMAPTGRM1
SCHEMBL642835 0.81 EGFR (0.64) EGFRERBB2LMNAKDR
SCHEMBL642834 0.81 EGFR (0.64) EGFRERBB2LMNAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575591-A4 HETEROCYCLES AND USES THEREOF ARIAD PHARMA INC (US) 2007-09-12 EP disclosed
US-7238679-B2 Heterocycles and uses thereof ARIAD PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
EP-1575591-A1 HETEROCYCLES AND USES THEREOF ARIAD PHARMACEUTICALS, INC. (US) 2005-09-21 EP disclosed
US-20040171586-A1 Heterocycles and uses thereof ARIAD PHARMACEUTICALS, INC. 2004-09-02 US disclosed
WO-2004058267-A1 HETEROCYCLES AND USES THEREOF ARIAD PHARMACEUTICALS, INC. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171586-A1 Heterocycles and uses thereof CBR1, CBR3, RCOR1 EGFR 1508/4885MAPK1 3766/4885KDM4E 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.